The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Self-citationBuzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Endocrine treatment of breast cancer in women
SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-221 · Cited by 399
Geisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P., & Lønning, P. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.531 · Cited by 336
Dowsett, M., Jones, A. L., Johnston, S. R. D., Jacobs, S., Trunet, P. F., & Smith, I. E. (1995) · PubMed · Cited by 258
Jonat, W., Howell, A., Blomqvist, C., Eiermann, W., Winblad, G., Tyrrell, C., Mauriac, L., Roche, H., Lundgren, S., Hellmund, R., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00014-3 · Cited by 254
Bhatnagar, A. S., Häusler, A., Schieweck, K., Lang, M., & Bowman, R. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90460-3 · Cited by 246
Buzdar, A. U., Jones, S. E., Vogel, C. L., Wolter, J., Plourde, P., Webster, A., & for the Arimidex Study Group (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<730::aid-cncr10>3.0.co;2-0 · Cited by 207
Evans, T. R. J., di Salle, E., Ornati, G., Lassus, M., Benedetti, M. S., Pianezzola, E., & Coombes, R. C. (1992) · PubMed · Cited by 161
Self-citation(1993) · PubMed · Cited by 130
Cited by
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Self-citationAromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.194 · Cited by 746
Self-citationGeisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.751 · Cited by 604
History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target
Santen, R. J., Brodie, H., Simpson, E. R., Siiteri, P. K., & Brodie, A. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0016 · Cited by 442
Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., & Brady, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3357 · Cited by 365
Boulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., & Lane, H. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2402 · Cited by 335
Robertson, J. F. R., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., Kleeberg, U. R., Come, S. E., Vergote, I., Gertler, S., et al. (2003) · Cancer · doi:10.1002/cncr.11468 · Cited by 315
Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer
Goss, P. E., & Strasser, K. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.881 · Cited by 298
Buzdar, A. U., Robertson, J. F. R., Eiermann, W., & Nabholtz, J. (2002) · Cancer · doi:10.1002/cncr.10908 · Cited by 290
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Gibson, L., Lawrence, D., Dawson, C., & Bliss, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003370.pub3 · Cited by 252
Influence of Sex Hormones on Cancer Progression
Folkerd, E. J., & Dowsett, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4290 · Cited by 229
Aromatase inhibitors: the next generation of therapeutics for endometriosis?
Attar, E., & Bulun, S. E. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.09.064 · Cited by 184
Letrozole: A Review of its Use in Postmenopausal Women with Advanced Breast Cancer
Lamb, H. M., & Adkins, J. C. (1998) · Drugs · doi:10.2165/00003495-199856060-00020 · Cited by 109
“Where stated, the duration of treatment ranged from 2 to 78 weeks,[38] was >8 weeks[40] or was a median of about 5 months.[42] The primary efficacy variable in all studies was overall objective response rate using International Union Against Cancer criteria, except in one phase II trial.”
InfluentialPfister, C. U., Martoni, A., Zamagni, C., Lelli, G., De Braud, F., Souppart, C., Duval, M., & Hornberger, U. (2001) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.273 · Cited by 101
Dranitsaris, G., Leung, P., Mather, J., & Oza, A. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200008000-00012 · Cited by 38
Hormone replacement therapy and women with premature menopause–a cancer survivorship issue
King, J., Wynne, C. H., Assersohn, L., & Jones, A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.007 · Cited by 34
(2011) · Cited by 12
Metadata
- Authors
- Gershanovich, M., Chaudri, H. A., Campos, D., Lurie, H., Bonaventura, A., Jeffrey, M., Buzzi, F., Bodrogi, I., Ludwig, H., Reichardt, P., O’Higgins, N., Romieu, G., Friederich, P., & Lassus, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 1998-06
- Volume
- 9
- Issue
- 6
- Pages
- 639-645
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2171423946
- Cited by
- 259
- References
- 24
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.